Latest Breaking News On - William chou - Page 6 : comparemela.com

Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

University of pennsylvaniaUnited statesStuart hendersonpassage bioWilliam chouPassage bio incMike beyersam brown incUniversity of pennsylvania gene therapy programHealthcare communicationsGoldman sachsAnnual global healthcare conferenceDana pointPassage bioGene therapy programBio investorsBio mediaMike beyersam brown

Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

PHILADELPHIA, March 27, 2023 Passage Bio, Inc. , a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced. | March 27, 2023

New yorkUnited statesUniversity of pennsylvaniaWilliam chouMike beyerStuart hendersonPassage bio incUniversity of pennsylvania gene therapy programHealthcare communicationsSam brown incGuggenheim healthcare talksGenomic medicinesRare disease daysPassage bioGene therapy programBio investors

Form 10-K Passage BIO, Inc For: Dec 31

Form 10-K Passage BIO, Inc For: Dec 31
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCommerce squareNew jerseyUniversity of pennsylvaniaSimona kingMaxine gowenSandip kapadiaAthena countouriotisEdgarb caleMichael kamarckTom woiwodeJames wilsonSaqib islamWilliam chouDerrell porter

Passage Bio (PASG) Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

Passage Bio (PASG) Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mark formanWilliam chouPassage bio incClinical development

Passage Bio Announces Positive Interim Clinical Data from

Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profileIntra-cisterna magna.

United statesUniversity of pennsylvaniaStuart hendersonMark formanMike beyerWilliam chouUniversity of pennsylvania gene therapy programEuropean commissionDrug administrationPassage bio incHealthcare communicationsSam brown incExchange commissionClinical developmentPassage bioOrphan drug